Navigation Links


Abbott at Biology News

Abbott at Biology Products
Abbott at Biology Technology

A prognosis for GE and Abbott Diagnostics

It is a...

Abbott vs. Thailand has implications for innovation and access

story regarding its Kaletra AIDS drug and the conflict with the government of Thailand over patent protection and drug pricing. Some of you may regard this as a relatively isolated tiff between a single drug company and another developing country. Others consider this to be a...

Wisconsin court halts Abbott's sale of genotyping products

, preventing the pharmaceutical company from further sales or use of products or components that infringe on a genotyping patent held by <a href="http://www.innogenetics.com...

Wisconsin court affirms damages in Innogenetics, Abbott patent case

Madison, Wis. - The The Madison-based court affirmed the damage award to , a biopharmaceutical company based in Gent, Belg...

Abbott Labs campus in Kenosha could send ripples through local biotech

While Abbott has set t...

More>>

Abbott at Medicine News

Pharmacia may take 51.5 percent Abbott stake

PHARMACIA Corp is close to signing a deal to acquire the 51.5 per cent stake in Abbott Laboratories India held by fellow US drugmaker Abbott Laboratories Inc. An industry source who declined to be identified, said Pharmacia could reach an agreement in the next few days to buy the stake in Abbott Laboratories India. // "If all goes well, senior Abbott officials from the company’s regi...

Abbott Laboratories to buy Biocompatibles' cardiovascular stent business

Abbott Laboratories said it has agreed to acquire the cardiovascular stent business of Biocompatibles International PLC for $234.5 million in cash. Abbott said the deal will strengthen its portfolio of products and will expand its international presence in the vascular business for polymer-coated stents - tiny metal tubes that keep blood vessels open.// Abbott has been the exclusive U...

Abbott’s Laboratories R&D Capabilities Questione

Abbott Laboratories shares fell by 1.3% to close at $43.80 following U.S. Food and Drug Administration (FDA) rejection of its new drug Xinlay. Increased number of scientists and analysts question the efficiency of Abbott’s R&D // , after the rejection of its drug. The drug that is to be used for the treatment of Prostate cancer failed in its Phase III trial leading to disapproval of the...

Abbott Receives CE Mark Certification

The CE Mark certification has been received by the global healthcare company Abbott towards a new test for detecting the Neissera gonorrhoeae (NG) and Chlamydia trachomatis // (CT) sexually transmitted pathogens. This will enable the company to sell the product in the European Union (EU). The test will be conducted through the Abbott m2000?, which uses real time polymerase chain reaction (PCR) an...

Abbott to Subsidize Price of HIV Drug

The US-based pharmaceutical multi-national, the Abbott, has agreed to lower the prices of Kaletra/Aluvia in low and low-middle income countries to one thousand// US dollars, on a request from the World Health Organization’s Director-General Margaret Chan. Kaletra is indicated for the treatment of HIV-1 infected adults and children above the age of 2 years, in combination with other ant...

More>>

Abbott at Medicine Products

ABBOTT PRISM

Description:The ABBOTT PRISM is a fully automated, high-volume blood screening instrument designed to enhance the safety of the blood supply. Before a blood donation can enter the blood supply, it is tested for evidence of exposure to viruses that might cause disease. This screening process involves numerous assays, multiple test instruments and many manual steps. The ABBOTT PRISM instrument consolidates muc...
Company:Abbott Diagnostics
Abbott at Medicine Technology

Three Studies Suggest Abbott's Humira (adalimumab) May Improve Work Productivity in Patients with Rheumatoid Arthritis

One Groundbreaking Study Showed 11 Percent Fewer RA PatientsReported Job Loss When Treated With HUMIRA Combination TherapyCompared to Methotrexate Alone BARCELONA, Spain, June 15, 2007 /PRNewswire-FirstCall/ --Rheumatoid arthritis (RA) is one of the most common causes ofdisability in the Western world. New data released today show thatrheumatoid arthritis (RA) patients treated with Abbott...

Abbott Announces Positive Nine-Month Results From the World's First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent

Absorbable Stent Continues to Show Promise as Future-GenerationTechnology BARCELONA, Spain, May 22, 2007 /PRNewswire-FirstCall/ -- Abbotttoday announced positive results from ABSORB, the world's firstclinical trial evaluating the safety and performance of a fullybioabsorbable drug eluting stent platform for the treatment ofcoronary artery disease. Nine-month results from the first 30pati...

Abbott Announces Continued Positive Results with Xience V Everolimus Eluting Coronary Stent in Spirit Clinical Trials

SPIRIT FIRST Demonstrates Continued Safety for XIENCE V with NoLate Stent Thrombosis or Additional Major Adverse Cardiac EventsOut to Three Years BARCELONA, Spain, May 22, 2007 /PRNewswire-FirstCall/ --Three-year data from the SPIRIT FIRST trial demonstrated noadditional Major Adverse Cardiac Events (MACE), and no late stentthrombosis in patients treated with either Abbott's XIENCE(TM) V...

New Analysis of Data Shows Treatment With Abbott's Humira (Adalimumab) Significantly Reduced Disease-Related Hospitalization for Patients with Crohn's Disease

HUMIRA Data Showed 57 Percent Reduction in Risk of Hospitalizationfrom Crohn's Disease vs. Placebo at One Year ABBOTT PARK, Ill., May 22, 2007 /PRNewswire-FirstCall/ -- Abbotttoday announced results from a post-hoc analysis of a pivotal studypresented at the Digestive Disease Week annual meeting inWashington, D.C. showing patients with moderate to severely activeCrohn's disease treated wi...

Abbott's Investigational Treatment ABT-874 Shows Positive Results in Phase II Psoriasis Study

Most Patients Achieved at Least 75 Percent Improvement in PsoriasisSigns and Symptoms at Week 12; in Four of Five Dosing Groups, MoreThan Half Achieved 90 Percent Improvement ABBOTT PARK, Ill., May 04, 2007 /PRNewswire-FirstCall/ -- NewPhase II study results show Abbott's investigational treatment,ABT-874, reduced psoriasis symptoms significantly in the majorityof patients treated. At 12...

More>>

Other TagsLangLangLangLang
(Date:10/10/2008)...lping people address health needs, INDIANAPOLIS, ...ng,economic times, people may be unable to make th...on,t have the money to visit their doctor or fill ...nal Association of,Insurance Commissioners (NAIC) ...t of Americans say that they have cut back on the,...
(Date:10/10/2008)...etion of a highly successful CIO Finance Summit 20...s their next business technology gathering, and th...s in healthcare. CDM Media has confirmed the CIO H...e Four Seasons Resort in Scottsdale, AZ. , ... 2008 -- Upon the completion of a highly successfu...
(Date:10/10/2008)...SNewswire/ -- Public interest,advocates(1) welcome...,decisions on the threats posed by mercury to huma...e 2nd UNEP(2) Open Ended Working Group (OEWG2) on,...t of a global framework,on mercury, in preparation...009, where it will be decided whether a global leg...
(Date:10/10/2008)... Technology Evolution: Smarter Solutions for Bette...A (PRWEB) September 17, 2008 -- The New Jersey and...re Information Management Systems Society ( HIMSS ...rmation technology professionals together for a tw...Technology Evolution: Smarter Solutions for Better...
Breaking Medicine News(10 mins):Health News:Healthcare Resources Available in Difficult Times 2Health News:Healthcare Resources Available in Difficult Times 3Health News:CIO Healthcare Summit Announces Dates and VIP Delegates 2Health News:Elements for a UN Global Framework on Mercury Agreed to 2Health News:HIMSS New Jersey and Delaware Valley Chapters Sponsor Regional Conference 2
(Date:10/10/2008)...and Swiss scientists conducted intensive studies o...f the glaciers, mountains and valleys. Around the ...t eight months in the region at locations above 50...n glaciers. , Now, fifty years later, the black ...e of immense value in trying to understand the imp...
(Date:10/10/2008)... DNA, the molecule that acts as the carrier of gen...esistant against alteration by ultraviolet light, ...lity presents some puzzling problems. A key aspect...s that make up the DNA molecule. Researchers at Ki...trands differ in their light sensitivity depending...
(Date:10/9/2008)...stCall/ -- Synaptics(R),Incorporated (Nasdaq: SYN...ons for mobile computing, communications, and ente...port financial results for the first quarter,of fi...close of market. The,company will host a correspon... 2:00 p.m. PT (5:00 p.m. ET) during which manageme...
(Date:10/9/2008)...o respond? Biodiversity in a Warmer World, publish...ence , illustrates that cross-disciplinary researc...stitute in Panama clearly informs this urgent deba...t and coral reefs, the tropics may have the most t...e, arguing that tropical organisms will be favored...
Breaking Biology News(10 mins):'Himalaya -- Changing Landscapes' photo exhibition draws attention to the impacts of climate change 2'Himalaya -- Changing Landscapes' photo exhibition draws attention to the impacts of climate change 3Can genetic information be controlled by light? 2Synaptics to Report First Quarter Results on October 23 2Smithsonian perspective: Biodiversity in a warmer world 2Aware Inc Announces Richard Moberg to Return as CFO 1634 1Aware Inc Announces Richard Moberg to Return as CFO 1634 2Aware Inc Announces Richard Moberg to Return as CFO 1634 3 Sunlight Helps Put Lung Cancer in the Shade 8426 1 Sunlight Helps Put Lung Cancer in the Shade 8426 2 Sunlight Helps Put Lung Cancer in the Shade 8426 3Labor 26 Medical Industry Give 56 25 of Prop 93 24 24 to Win Concessions in Health Care Legislation 8422 1Labor 26 Medical Industry Give 56 25 of Prop 93 24 24 to Win Concessions in Health Care Legislation 8422 2Labor 26 Medical Industry Give 56 25 of Prop 93 24 24 to Win Concessions in Health Care Legislation 8422 3Baxter Announces FDA Approval of GELFOAM 28R 29 Plus Hemostasis Kit 2253 1Baxter Announces FDA Approval of GELFOAM 28R 29 Plus Hemostasis Kit 2253 2Baxter Announces FDA Approval of GELFOAM 28R 29 Plus Hemostasis Kit 2253 3Baxter Announces FDA Approval of GELFOAM 28R 29 Plus Hemostasis Kit 2253 4
Other Contentstropicaltropicaltropicaltropicaltropicaltropicallevellevellevellevellevellevellevellevellevelleveltriglyceridetriglyceridetriglyceridetriglyceridearteriosustrypanosomiasistryptophantryptophantryptophantryptophan